ahsct vs. high-activity dmts in ms treatment
Published 1 year ago • 347 plays • Length 7:36Download video MP4
Download video MP3
Similar videos
-
1:44
guidelines for ahsct in ms
-
3:49
ahsct in multiple sclerosis
-
2:12
early initiation of high-efficacy dmts in ms
-
0:47
when to make a timely switch to high-efficacy dmt for ms
-
2:13
repositioning hsct in the ms treatment algorithm
-
1:03
future studies on ahsct for multiple sclerosis
-
2:57
initial high-efficacy disease-modifying therapy in multiple sclerosis
-
46:14
the case for offering ahsct as a first-line treatment for ms
-
1:51
safety and efficacy of ahsct for ms
-
2:11
when should dmts be stopped when treating ms?
-
6:17
early intensive ms treatment versus escalation approach: a comprehensive study
-
1:11
comparative effectiveness and persistence of cladribine versus other oral dmts in ms
-
14:49
“choosing the right disease-modifying therapy,” geeta ganesh, m.d.
-
8:45
what role does autologous haematopoietic stem cell transplant (ahsct) play in ms treatment?
-
31:37
highly effective disease-modifying therapies for multiple sclerosis
-
4:03
the predictive value of neda-3 for long-term disability in ms
-
40:44
harnessing the full potential of dmt mechanisms of action to improve ms outcomes
-
3:14
using dmts beyond patients with active ms
-
3:19
chariotms: the first dmt trial in advanced multiple sclerosis